Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-01

Study Completion Date

2020-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will evaluate distal intestinal bile salt administration in humans by deliving ursodeoxycholic acid (UDCA) into the terminal ileum of subjects with a pre-existing ileostomy and assessing several hormone levels following an oral glucose tolerance test compared to a placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Bile Acids in Patients With Peroxisomal Disorders

NCT00004442

Infantile Refsum's Disease Zellweger Syndrome Bifunctional Enzyme Deficiency +1 more

TERMINATED NA

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

NCT02464020

Primary Sclerosing Cholangitis Inflammatory Bowel Disease

COMPLETED PHASE1

Restoring the Beneficial Effects of Enterohepatic Bile Salt Signalling by Chyme Reinfusion in Patients With a Double Enterostomy

NCT02990195

Double Enterostomy

COMPLETED PHASE2

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

NCT02871882

Type 2 Diabetes Mellitus Obese Overweight

COMPLETED PHASE2

Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis

NCT05043194

Cholestasis of Parenteral Nutrition

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ursodeoxycholic acid (UDCA) is currently FDA-approved for the treatment of gallstone dissolution and primary biliary cirrhosis. Other than these two diseases, exploratory research - both preclinical and clinical - has demonstrated other beneficial effects of UDCA. For example, systemic administration of UDCA for several weeks (4-6 weeks) has been shown to improve insulin sensitivity in non-diabetic, obese individuals. Whether or not these effects on insulin sensitivity may be acute in nature and are detectable by OGTT are unknown. Based on growing knowledge of bile salt receptors in the gastrointestinal tract, at least some of these effects of bile salts on metabolism appear to be mediated by receptors constitutively expressed in the terminal ileum (e.g. TGR5 receptor that is upstream of GLP-1 and insulin secretion that control blood glucose levels). Thus, metabolic effects may be inducible with acute UDCA administration directly into this region of the intestine that could be useful in screening compounds or designing future mechanistic studies. This pilot study is designed to examine the effects of UDCA on oral glucose tolerance versus a placebo in non-diabetic across a range of body mass indexes by infusing UDCA directly into the ileum of volunteering subjects with a pre-existing ileostomy and measuring hormone response. The investigators aim to recruit approximately 4-5 volunteers in a lean BMI range (18.5-25 kg/m2), overweight (\>25-29.9), class 1 obesity (\>30-35 kg/m2), and class 2 obesity (\>35-40 kg/m2) for a total of \~16-20 participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glucose Intolerance Gastric Bypass Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Each volunteering subject will participate in 2 study visits, receiving the placebo at one visit and investigation medication at the other visit. The order of these visits will be randomized.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ursodeoxycholic Acid/Placebos

During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.

Group Type ACTIVE_COMPARATOR

Ursodeoxycholic Acid

Intervention Type DRUG

Ileostomy administration of 300mg UDCA once

Placebos

Intervention Type DRUG

Ileostomy administration of 5cc saline placebo once

Placebos/Ursodeoxycholic Acid

Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.

Group Type ACTIVE_COMPARATOR

Ursodeoxycholic Acid

Intervention Type DRUG

Ileostomy administration of 300mg UDCA once

Placebos

Intervention Type DRUG

Ileostomy administration of 5cc saline placebo once

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ursodeoxycholic Acid

Ileostomy administration of 300mg UDCA once

Intervention Type DRUG

Placebos

Ileostomy administration of 5cc saline placebo once

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UDCA Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to give informed consent
* Presence of an ileostomy \> 2 months
* Weight stable\* for \>2 months (i.e. no greater than 7% change in body weight the last 2 months)

Exclusion Criteria

* Crohn's Disease
* Steroid use in the last 3 months
* Documented/known diagnosis of type 1 diabetes or type 2 diabetes, chronic liver disease, chronic kidney disease, heart failure, cardiac dysrhythmias, or familial hypercholesterolemia
* Current use of any over-the-counter or prescription oral bile salt
* Currently pregnant
* Current use of medications that are known to interact with Ursodiol
* Current or former smoker within the last year.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes